These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24901552)

  • 41. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. U.S. patent law. Case probes what's fair game in the search for new drugs.
    Kintisch E
    Science; 2005 Apr; 308(5719):174. PubMed ID: 15821048
    [No Abstract]   [Full Text] [Related]  

  • 43. Patent-sharing scheme for neglected diseases may have catch.
    Waters H
    Nat Med; 2011 Dec; 17(12):1529. PubMed ID: 22146436
    [No Abstract]   [Full Text] [Related]  

  • 44. Genetic patent protection in the pharmaceutical and biotechnology industries.
    Nunnally AC; Webster CJ; Brown SA; Cohen GA
    Community Genet; 2005; 8(4):209-16. PubMed ID: 16244474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Getting the most out of your IP--patent management along its life cycle.
    Bader MA; Gassmann O; Ziegler N; Ruether F
    Drug Discov Today; 2012 Apr; 17(7-8):281-4. PubMed ID: 22079191
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Merck, SmithKline and patents.
    Caskey CT; Williamson AR
    Nature; 1996 May; 381(6581):360. PubMed ID: 8632785
    [No Abstract]   [Full Text] [Related]  

  • 47. [Intellectual property rights and right of access to medicines].
    Velásquez G
    Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
    Grabowski HG; Moe JL
    Cancer Prev Res (Phila); 2008 Jul; 1(2):84-90. PubMed ID: 19138940
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug patents and intellectual property rights.
    Raj GM; Priyadarshini R; Mathaiyan J
    Eur J Clin Pharmacol; 2015 Apr; 71(4):403-9. PubMed ID: 25640303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system.
    Kesselheim AS
    AAPS J; 2007 Aug; 9(3):E306-11. PubMed ID: 17915832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

  • 52. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
    Sahoo N; Manchikanti P
    BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Undermining TRIPS: protectionism at its worst.
    Lancet; 2007 Jan; 369(9555):2. PubMed ID: 17208619
    [No Abstract]   [Full Text] [Related]  

  • 54. Are pharmaceutical patents protected by human rights?
    Millum J
    J Med Ethics; 2008 Nov; 34(11):e25. PubMed ID: 18974405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patenting bioactive molecules from biodiversity: the Brazilian experience.
    Nogueira RC; de Cerqueira HF; Soares MB
    Expert Opin Ther Pat; 2010 Feb; 20(2):145-57. PubMed ID: 20099999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Colchicine's other indication--effect of FDA action.
    Grody WW; Getzug T
    N Engl J Med; 2010 Dec; 363(23):2267-8. PubMed ID: 21121853
    [No Abstract]   [Full Text] [Related]  

  • 57. Big companies helped by safe harbour ruling.
    Frantz S
    Nat Rev Drug Discov; 2005 Jul; 4(7):525-6. PubMed ID: 16075481
    [No Abstract]   [Full Text] [Related]  

  • 58. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

  • 59. USA-Morocco deal may extend drug patents to 30 years.
    Ahmad K
    Lancet; 2003 Dec; 362(9399):1904. PubMed ID: 14672079
    [No Abstract]   [Full Text] [Related]  

  • 60. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.